Results 41 to 50 of about 2,517,915 (228)

Psychedelics: A new era of treatment?

European Psychiatry, 2021
Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations.
S. Torres
doaj   +1 more source

Pengalaman Anak Jalanan Usia Remaja Dalam Perilaku Inhalasi Lysergic Acid Diethylamide

Jurnal Ilmu Keperawatan Anak, 2019
Seorang anak bisa menjadi anak jalanan tentu mempunyai hal yang melatarbelakangi dalam kehidupannya. Sehingga anak jalanan sangat rentan untuk terjerumus kedalam perilaku menyimpang salah satunya adalah perilaku inhalasi zat adiktif seperti Lysergic Acid
Chatarina Suryaningsih, Soleha Hendarsyah   +1 more
doaj   +1 more source

Pharmacokinetics and concentration-effect relationship of oral LSD in humans [PDF]

, 2015
BACKGROUND: The pharmacokinetics of oral lysergic acid diethylamide are unknown despite its common recreational use and renewed interest in its use in psychiatric research and practice.
Dolder, Patrick C., Rentsch, Katharina M., Liechti, Matthias E., Schmid, Yasmin, Haschke, Manuel   +4 more
core   +1 more source

Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice

Frontiers in Pharmacology, 2023
The classical psychedelic psilocybin is of interest as a treatment for alcohol use disorder (AUD). This study investigated the effects of psilocybin on voluntary ethanol consumption in adult male and female C57BL/6J mice administered saline or psilocybin
Kenneth Alper, Kenneth Alper, Janelle Cange, Ria Sah, Deanna Schreiber-Gregory, Henry Sershen, Henry Sershen, K. Yaragudri Vinod, K. Yaragudri Vinod, K. Yaragudri Vinod   +9 more
doaj   +1 more source

Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice

Journal of Psychopharmacology, 2021
Background: The reticular thalamus gates thalamocortical information flow via finely tuned inhibition of thalamocortical cells in the mediodorsal thalamus.
A. Inserra, D. De Gregorio, Tamim Rezai, M. López-Canúl, S. Comai, G. Gobbi   +5 more
semanticscholar   +1 more source

Lysergic acid diethylamide (LSD) [PDF]

, 2019
Lysergic acid diethylamide (LSD) is a drug known for its hallucinogenic properties especially at high doses and in recent years has been used as a pharmacological model to study the neurological substrate of psychosis, the effect of antipsychotics, and ...
Kehayova, Gabriela; Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University of Varna, Bulgaria, Marinov, Petko; Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University of Varna, Bulgaria, Zlateva, Snezha; Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University of Varna, Bulgaria   +2 more
core   +2 more sources

The Theoretical Synthesis and in silico Modelling of Lysergic Acid Biscinnamylidene Amide from the Adduct Formation of d-Lysergic Acid Amide and Cinnamaldehyde

, 2022
Here is a theoretical synthesis for a cinnamaldehyde adduct formation of a hypothetically proposed lysergamide derivative named cinnamylidene-bislysergamide or lysergic acid biscinnamylidene amide (LSBC).
Chiruta, Victor
core   +1 more source

Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2’S,4’S)-lysergic acid 2,4-dimethylazetidide (LSZ)

Drug Testing and Analysis, 2016
Lysergic N,N-diethylamide (LSD) is perhaps one of the most intriguing psychoactive substances known and numerous analogs have been explored to a varying extent in previous decades.
Simon D. Brandt, P. Kavanagh, F. Westphal, S. Elliott, J. Wallach, Tristan Colestock, T. Burrow, S. J. Chapman, A. Stratford, D. E. Nichols, A. Halberstadt   +10 more
semanticscholar   +1 more source

An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)

Pilot and Feasibility Studies, 2023
Background Globally, an estimated 260 million people suffer from depression [1], and there is a clear need for the development of new, alternative antidepressant therapies.
Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner, David Menkes, William Evans, Nicholas Hoeh, Frederick Sundram, Lisa Reynolds, Rhys Ponton, Alana Cavadino, Todd Smith, Partha Roop, Nathan Allen, Binu Abeysinghe, Darren Svirskis, Anna Forsyth, Mahima Bansal, Suresh Muthukumaraswamy   +17 more
doaj   +1 more source

Acute effects of lysergic acid diethylamide (LSD) on resting brain function

Swiss Medical Weekly, 2019
Lysergic acid diethylamide (LSD) is a potent hallucinogenic substance that was extensively investigated by psychiatrists during the 1950s and 1960s.
Felix Müller, Stefan Borgwardt
doaj   +1 more source